Molecular Profile Detail

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 27 of 27 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
EML4 - ALK ALK I1171S	lung non-small cell carcinoma	predicted - resistant		Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, a patient with EML4-ALK positive non-small cell lung cancer initially responded to Alecensa (alectinib), but progressed with the emergence of a secondary ALK I1171S mutation (PMID: 25393796).	25393796
EML4 - ALK ALK I1171S	lung adenocarcinoma	predicted - resistant		Crizotinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK I1171S was identified on post-progression biopsy in a patient with metastatic lung adenocarcinoma harboring EML4-ALK, who previously responded to Xalkori (crizotinib) (PMID: 36324562).	36324562
EML4 - ALK ALK I1171S	lung adenocarcinoma	predicted - sensitive		Ceritinib	Case Reports/Case Series	Actionable	In a clinical case study, Zykadia (ceritinib) treatment resulted in tumor shrinkage with a progression-free survival of at least 8 months in a patient with metastatic lung adenocarcinoma harboring EML4-ALK and ALK I1171S (PMID: 36324562).	36324562
EML4 - ALK ALK I1171S	lung adenocarcinoma	predicted - resistant		Alectinib	Case Reports/Case Series	Actionable	In a clinical case study, ALK I1171S was identified on post-progression biopsy in a patient with lung adenocarcinoma harboring EML4-ALK (e6:e19) who previously responded to Alecensa (alectinib) treatment (PMID: 29981924).	29981924
EML4 - ALK ALK I1171S	lung adenocarcinoma	predicted - sensitive		Brigatinib	Case Reports/Case Series	Actionable	In a clinical case study, Alunbrig (brigatinib) treatment resulted in a partial response with regression of the liver lesions and disease control in the intrathoracic and brain metastases lasting at least 9 months in a patient with lung adenocarcinoma harboring EML4-ALK (e6:e19) and ALK I1171S (PMID: 29981924).	29981924
EML4 - ALK ALK I1171S	Advanced Solid Tumor	resistant		Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Xalkori (crizotinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
EML4 - ALK ALK I1171S	Advanced Solid Tumor	resistant		Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Alecensa (alectinib) mediated growth inhibition in culture (PMID: 27009859).	27009859
EML4 - ALK ALK I1171S	Advanced Solid Tumor	resistant		ASP3026	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to ASP3026 mediated growth inhibition in culture (PMID: 27009859).	27009859
EML4 - ALK ALK I1171S	Advanced Solid Tumor	resistant		AZD3463	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to AZD3463 mediated growth inhibition in culture (PMID: 27009859).	27009859
EML4 - ALK ALK I1171S	Advanced Solid Tumor	sensitive	Lorlatinib	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells co-expressing EML4-ALK and ALK I1171S demonstrated sensitivity to treatment with Lorbrena (lorlatinib) in culture (PMID: 27432227).	27432227
EML4 - ALK ALK I1171S	Advanced Solid Tumor	conflicting		Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) reduced ALK phosphorylation and inhibited growth of transformed cells expressing EML4-ALK with ALK I1171S in culture (PMID: 31943796).	31943796
EML4 - ALK ALK I1171S	Advanced Solid Tumor	conflicting		Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited growth of transformed cells expressing EML4-ALK with ALK I1171S in culture (PMID: 27432227).	27432227
EML4 - ALK ALK I1171S	Advanced Solid Tumor	conflicting		Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Zykadia (ceritinib)-mediated growth inhibition in culture (PMID: 27009859).	27009859
EML4 - ALK ALK I1171S	Advanced Solid Tumor	conflicting		Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) reduced ALK phosphorylation and inhibited growth of transformed cells expressing EML4-ALK with ALK I1171S in culture (PMID: 31943796).	31943796
EML4 - ALK ALK I1171S	Advanced Solid Tumor	conflicting		Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Alunbrig (brigatinib)-mediated growth inhibition in culture (PMID: 27009859).	27009859
EML4 - ALK ALK I1171S	Advanced Solid Tumor	conflicting		Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited growth of transformed cells expressing EML4-ALK with ALK I1171S in culture (PMID: 27432227).	27432227
EML4 - ALK ALK I1171S	Advanced Solid Tumor	resistant		TPX-0131	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing ALK I1171S in the context of EML4-ALK were resistant to TPX-0131 in culture (PMID: 34158340).	34158340
EML4 - ALK ALK I1171S	Advanced Solid Tumor	resistant		Crizotinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Xalkori (crizotinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171S	Advanced Solid Tumor	resistant		Alectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Alecensa (alectinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171S	Advanced Solid Tumor	conflicting		Ceritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Zykadia (ceritinib) inhibited viability of transformed cells expressing EML4-ALK with ALK I1171S in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171S	Advanced Solid Tumor	conflicting		Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) inhibited viability of transformed cells expressing EML4-ALK with ALK I1171S in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171S	Advanced Solid Tumor	sensitive	Lorlatinib	Lorlatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Lorbrena (lorlatinib) inhibited viability of transformed cells expressing EML4-ALK with ALK I1171S in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171S	Advanced Solid Tumor	resistant		Entrectinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing EML4-ALK with ALK I1171S were resistant to Rozlytrek (entrectinib) in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171S	Advanced Solid Tumor	sensitive		Gilteritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Xospata (gilteritinib) inhibited viability of transformed cells expressing EML4-ALK with ALK I1171S in culture (PMID: 33627640).	33627640
EML4 - ALK ALK I1171S	Advanced Solid Tumor	sensitive		Iruplinalkib	Preclinical - Cell culture	Actionable	In a preclinical study, Iruplinalkib (WX-0593) treatment inhibited viability of transformed cells expressing EML4-ALK with ALK I1171S in culture (PMID: 35421578).	35421578
EML4 - ALK ALK I1171S	Advanced Solid Tumor	conflicting		Brigatinib	Preclinical - Cell culture	Actionable	In a preclinical study, Alunbrig (brigatinib) treatment inhibited viability of transformed cells expressing EML4-ALK with ALK I1171S in culture (PMID: 35421578).	35421578
EML4 - ALK ALK I1171S	Advanced Solid Tumor	predicted - sensitive		NVL-655	Preclinical - Cell culture	Actionable	In a preclinical study, NVL-655 moderately inhibited viability of cells expressing EML4-ALK and ALK I1171S in culture (PMID: 39269178).	39269178

Showing 1 to 27 of 27 entries

Filter rows:

Profile Name	EML4 - ALK ALK I1171S
Gene Variant Detail	ALK I1171S (unknown) EML4 - ALK (gain of function)
Relevant Treatment Approaches	Lorlatinib

Molecular Profile Detail

Contact

Filtering

Sorting